Skip to main content
Biocorp logo

Biocorp — Investor Relations & Filings

Ticker · ALCOR ISIN · FR0012788065 LEI · 969500TKUAME6031UQ32 PA Manufacturing
Open in API
Filings indexed 235 across all filing types
Latest filing 2020-01-14 Capital/Financing Update
Country FR France
Listing PA ALCOR

About Biocorp

https://biocorpsys.com

Biocorp designs, develops, and manufactures medical devices and drug delivery systems for the pharmaceutical industry. The company specializes in combining precision engineering with connected technologies to improve patient treatment adherence and outcomes. Its portfolio includes both connected and non-connected devices, such as smart caps for inhalers (Inspair), pen injectors, and systems for drug reconstitution and safety. Biocorp manages the entire value chain, from research and development to manufacturing and final packaging, leveraging its expertise in plastics processing and advanced technological innovation. Since October 2023, Biocorp has been a subsidiary of Novo Nordisk.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document announces a strengthened partnership and a new contract between BIOCORP and SANOFI regarding the Mallya device, including upfront payments and milestone payments. This clearly relates to financing activities, capital structure changes (in terms of partnership value/investment), and strategic business development involving financial commitments. This fits best under 'Capital/Financing Update' (CAP), as it details new financial arrangements and payments related to the collaboration, rather than being a general earnings release (ER) or a full annual/interim report (10-K/IR). It is not a merger (TAR) or a general regulatory filing (RNS).
2020-01-14 French
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "BIOCORP : Agenda financier 2020" and explicitly lists future dates for key corporate events: Annual Results (Résultats annuels 2019), Annual General Meeting (Assemblée Générale), and Half-Year Results (Résultats semestriels 2020). This document is an announcement detailing the schedule of future financial and corporate events, rather than the reports themselves (like 10-K or IR) or the AGM materials. Since it announces the date of the AGM (Vendredi 15 mai 2020), it relates closely to AGM information, but its primary function is scheduling future corporate announcements. It is not a full report, a transcript, or a specific regulatory filing like DIRS or DIV. Given the focus on scheduling future financial events and the AGM date, it is best classified as a general announcement regarding corporate events, which often falls under Regulatory Filings (RNS) if no other specific category fits perfectly, or potentially related to AGM information if the focus was on the meeting itself. However, since it is a forward-looking schedule announcement, and not the AGM materials (AGM-R) or the actual results (ER/IR), the most appropriate general category for scheduling announcements that don't fit elsewhere is RNS, or potentially a general Investor Relations document. Given the options, and that it is a forward-looking schedule announcement, RNS (Regulatory Filings/General Announcement) is the safest fit, although it is very close to an Investor Presentation (IP) or a general corporate update. Since it is a simple schedule announcement, RNS is the most appropriate fallback for non-specific scheduling disclosures.
2020-01-09 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Regulatory Filings Classification · 1% confidence The document is titled "Bilan annuel du contrat de liquidité BIOCORP confié à la société Kepler Chevreux" (Annual statement of the liquidity contract entrusted to Kepler Chevreux) and is dated January 9, 2020. It details the status of a liquidity contract, including the number of shares and cash held in the account as of December 31, 2019, and transaction volumes during the second half of 2019. This type of filing, which reports on specific financial arrangements like liquidity contracts or share buyback programs, fits best under 'Transaction in Own Shares' (POS) or potentially 'Capital/Financing Update' (CAP). Since liquidity contracts often involve the company managing its own shares (buying/selling to maintain liquidity), POS is the most specific fit for reporting on the activity of such a contract. It is not a general earnings release (ER), an annual report (10-K), or a general regulatory filing (RNS). Given the focus on share transactions related to market making/liquidity, POS is selected.
2020-01-09 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document title is "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It provides a table showing the total number of shares and voting rights as of December 31, 2019. This type of announcement, which details the total share count and voting power, is directly related to the company's capital structure and share issuance status. Among the provided definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate fit, as changes in the total number of shares directly impact the capital structure. Although it is not a direct announcement of a new issue, it is a mandatory periodic disclosure regarding the current state of the share capital, which falls under the scope of capital structure reporting. It is not an Earnings Release (ER), Interim Report (IR), or a general Regulatory Filing (RNS), as it is highly specific to share count.
2020-01-09 French
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document is titled 'BIOCORP: 2020 financial calendar' and explicitly lists the dates for future announcements, such as '2019 full-year results', 'Annual shareholders meeting', and '2020 first-half results'. It is not the actual financial report (like 10-K or IR) or the results announcement (ER/IR). Instead, it is an announcement about the schedule of future corporate events and report publications. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports.
2020-01-09 English
Inside Information / Other news releases
Board/Management Information Classification · 1% confidence The document explicitly announces changes in the company's leadership structure, specifically the separation of the Chairman and CEO roles, the appointment of Eric Dessertenne as the new CEO, and the continuation of Jacques Gardette as Chairman. This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management.
2019-12-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.